Objective: The purpose of this work was to identify and estimate a population pharmacokinetic-pharmacodynamic model for duodenal infusion of a levodopa/carbidopa gel (Duodopa) to examine pharmacological properties of this treatment.
Methods:
The modeling involved pooling data from 3 studies (on advanced Parkinson disease) and fixing some parameters to values found in literature. The first study involved 12 patients studied on 3 occasions each and was previously published. The second study involved 3 patients on 2 occasions. A bolus dose was given after a washout during night. Plasma samples and motor ratings (clinical assessment of motor function on a 7-point treatment response scale ranging from ''very off'' to ''very hyperkinetic'') were collected until the clinical effect returned to baseline. The third study involved 5 patients on 3 occasions receiving 5 different dose levels. Different structural models were evaluated using the nonlinear mixed-effects modeling program NONMEM VI. Population mean parameter values, and interindividual, interoccasion, and residual variabilities were estimated.
Results: Absorption of the levodopa/carbidopa gel can be adequately described with first-order absorption with bioavailability and lag time. Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%. The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an E max of 2.39 U on the treatment response scale, and a sigmoidicity of the E max function of 11.6. Conclusions: For the typical unmedicated subject, it will take 51.4 minutes until the peak levodopa effect is reached after a bolus dose. This delay is, like the magnitude of the effect, highly variable in this patient group. The residual error magnitudes of 20% for levodopa concentrations and 0.92 U (SD) for motor ratings indicate that the models developed provide predictions of a relevant quality. The developed model may be a first step toward model-guided treatment individualization of duodenal infusion of levodopa. 1 Oral administration and irregular gastric emptying cause fluctuations in plasma levodopa concentration, which are thought to cause corresponding fluctuations in the effect compartment with some time delay 2 and corresponding motor fluctuations. One way to proceed with treatment in the advanced stages is by intestinal administration of levodopa/carbidopa gel via an adjustable pump (Duodopa; Solvay Pharmaceuticals, Allschwil, Switzerland). This treatment has been shown to reduce variation in levodopa concentration and to increase the time in ''on state. '' 3,4 The infusion pump is typically shut off during the night, and the day starts with a morning bolus dose. Thereafter, a constant flow rate supplies an even levodopa level during the day.
Levodopa in presence of decarboxylase inhibitors follows 2-compartment kinetics, 5 and its clinical effect assessments are typically modeled using sigmoid E max models with a first-order delay compared with the plasma concentration. Effect site levodopa concentration is related to a clinical response by an S-shaped curve.
1,6Y8 As PD progresses, this curve gets steeper. 1, 6, 8 The purpose of this work was to identify and estimate characteristic parameters of a population pharmacokinetic-pharmacodynamic (PKPD) model for duodenal infusion of the levodopa/ carbidopa gel. This was done to achieve a better understanding of the pharmacological properties of this levodopa formulation.
METHODS

Studies and Subjects
The modeling involved pooling data from 3 studies and fixing levodopa disposition parameters to values found in literature. 5 The disposition of the patients in all the studies is shown in Table 1 . The first study involved levodopa plasma concentrations and motor function assessments from 12 infusion patients, studied on 3 occasions and was described by Nyholm et al 3 in 2003. It turned out that data from this study alone were insufficient for PKPD model identification because available levodopa plasma concentrations were generally stable. To successfully identify model parameters, doses giving both high and low concentrations and effects are required. A small additional study was therefore executed.
This second study, PEDAL, Parameter Estimation for Duodenal Administration of Levodopa, involved 3 patients studied on 2 occasions each. The study protocol was accepted by the ethics committee of the Karolinska Institute, Sweden, and the patients gave informed consent in accordance with the Helsinki declaration. A ''bolus'' dose (normal individual morning dose plus 50%) was given with the Duodopa pump after a washout during the night. Data collection continued until the clinical effect was back at baseline or, at most, 4 hours. At this point, the patient's normal infusion rate was started. Data were collected for another 2 hours. This procedure was performed on 2 nonconsecutive days per patient. Blood samples and effect measurements were collected in 5-to 15-minute intervals. The main effect variable was clinical assessment of motor function from video recordings on a treatment response scale (TRS) between j3 and 3, where j3 represents severe Parkinsonism and 3 represents severe choreatic dyskinesia. Details of this procedure are described previously. 4 Blood samples were immediately cold-centrifuged, and plasma samples were frozen in j70-C until analyzed by high performance liquid chromatography as previously described. 3 One patient (no. 101) was allowed to take levodopa up to 4 hours before the start of measurements, and 1 patient (no. 103) did not complete the second visit (consent withdrawn).
The third study, Nyholm et al (2010, unpublished data), involving 5 patients, was approved by the local ethics committee and the Swedish Medical Products Agency. Patients were studied during five 4-hour periods, in a total of 2.5 days, using 5 different infusion rates. Doses well adjusted and judged as good as possible for an individual (optimized) were used on the first half-day (day 1), whereas on day 2, 120% of the optimized dose was given on the first half-day and 90% of the optimized dose was given the second half-day. On day 3, 80% of the optimized dose was given the first half-day, and 110% was given the second half-day. All doses during test days 2 and 3 were blinded to patients. Sampling intervals were 20 to 30 minutes. Immediately after each blood sample, patients were video recorded while performing the standardized set of tasks for assessment on the TRS scale. Three raters independently performed the ratings in randomized order, and mean values were taken.
Modeling
The structure of the PKPD model is shown in Figure 1 . This model is described by the following set of ordinary differential equations:
Explanations of variables and parameters in Equations (1) to (4): Inf indicates levodopa infusion (mg/min); R syn , endogenous levodopa synthesis rate (mg/min); a i , amount (mg) in compartment i; V i , apparent volume (L) in compartment i; Q, intercompartmental clearance (L/min); BIO, bioavailability (fraction absorbed); Lag time, absorption lag time (minutes); and c e , effect compartment concentration (mg/L). This effect compartment model (Eq. [4] ) is identical to the one described by Sheiner et al. 10 The following derived PK parameters are defined: TABS = 1/k a , absorption time constant (minutes); TKEO = 1/k EO , effect time constant (minutes).
The sigmoid E max effect model is described by the following equation:
Explanations of variables and parameters in Equation (5): E indicates effect on the TRS scale; F, sigmoidicity (Hill) factor; EC 50 , concentration at 50% effect; BASE, baseline effect; E max , maximum effect (change from BASE).
The data set was too small to separately distinguish interindividual (IIV) and interoccasion variability (IOV) in parameters. Therefore, each occasion was treated as a separate patient, and the resulting parameter variability will approximate the sum of IIV and IOV (denoted IIV/IOV). This variability is modeled as described by the equations below, where P individual represents 9 †Stage assessed at worst. ‡Stage assessed during on. 
Various structural absorption models (Table 2A) and effect (pharmacodynamic) models (Table 2B) were evaluated using the value of the objective function in the NONMEM VI package (Icon Development Solutions, Ellicott City, Md). This objective function is proportional to the log likelihood of observing the data given the model. The difference in the objective function between 2 nested models follows a W 2 distribution where a value change of 4 U or more between 2 hierarchical models differing in 1 parameter is statistically significant (P G 0.05). Model identification and parameter estimation was done in 2 steps: Estimation of absorption parameters was based on dose and plasma levodopa concentration data, whereas pharmacodynamic parameters were estimated based on the concentration-time profile and effect data. Population mean parameter values, interindividual/interoccasion variability (IIV/IOV), residual variability, and their SEs were estimated using the first-order conditional estimation method in NONMEM. 
RESULTS
Estimated parameter values for the ''selected best models'' according to Tables 2A and B are presented in Table 3 . An adequate model for absorption of the duodenal infusion of the levodopa/carbidopa gel is first-order absorption (mean absorption time of 28.5 minutes) with a bioavailability of 88% and a lag time of 2.9 minutes (model no. 6 in Table 2A ). The parameters were relatively well determined with SEs of 4% to 43%. Individual variability (IIV/IOV) for bioavailability was not improving the model and is therefore not included. For absorption time, it was 43%, and it was large for the lag time (140%).
The best pharmacodynamic model was of the effect compartment sigmoid E max type with a steep sigmoidicity coefficient (Hill = 11.6; model no. 6 in Table 2B ). The EC 50 was 1.55 mg/L, but with an IIV/IOV of 64%. For the effect model, estimates of SE could not be obtained for the final model because of difficulties with the numerical estimation routines. Instead, SEs of a simpler model (no. 2 in Table 2B ) are presented. Figure 2 illustrates the model's ability to predict actual plasma concentrations and motor ratings in the patients from PEDAL and the third study (Nyholm et al, 2010 , unpublished data). The proportional random error in the PK predictions was 0.20, and the additive random error of the effect model predictions was 0.92.
DISCUSSION
To our knowledge, this is the first attempt to identify a PKPD model for the levodopa/carbidopa gel formulation. The absorption time seems slightly faster, and bioavailability is larger for infusion of the levodopa/carbidopa gel compared with oral levodopa, whereas pharmacodynamic parameters are similar to those found in other studies.
1,6Y8 On average, 88% of infused dose will be absorbed, and it will take 51.4 minutes until a momentary bolus dose (without any subsequent continuous dose) gets peak effect from an unmedicated condition in a typical patient. The effect is very sensitive to concentration changes around the EC 50 in this patient group, and there is a large individual variability in EC 50 (64% coefficient of variation), which corresponds to the large interindividual variability in dosage. 11 As far as we know, this is also the first attempt to model both ''off'' symptoms and peak dose dyskinesia symptoms in the same scale (the TRS). As seen in Figure 2 , the absorption and effect models were reasonably successful in fitting observed data. Clearly, motor ratings are more difficult to predict than levodopa plasma concentrations. Effect parameters' (the therapeutic window's) interindividual variability is large, and therefore, the average individual's prediction deviates substantially from the specific individuals' predictions and the observed data.
This PKPD modeling is based on data from a total of 20 patients, which may be considered a small number, but on the other hand, these were intensively studied on several occasions. Further, literature information was used to support the present investigation with respect to levodopa disposition. Twelve of the patients 3 were novel to infusion treatment and received the treatment through a nasoduodenal tube. The other 8 patients had the permanent percutaneous endoscopic gastrojejunostomy (PEG-J) placement and were stable on the treatment. Obviously, dosage during experimental days was varied to provide information about the dose-concentration effect relationships. The 5 patients in Nyholm et al (2010, unpublished data) were selected specifically for having severe, difficult-to-treat dyskinesias. Owing to the difficulty in obtaining SEs of estimates for the pharmacodynamic parameters, these estimates, in particular, those of variability components, should be regarded with caution. Further, the TRS ratings were originally given on a discrete, ordered scale, and we used them as an interval scale, which may influence interpretation of results.
The only covariate used was body weight, and this was only used in the PK model. It is well known that factors other than levodopa concentration may influence parkinsonian motor symptoms. These factors include stress level, food intake, time of day, physical activity, intake of other pharmaceuticals affecting dopaminergic, or other receptors. None of these factors are included in the present model, and these will therefore seem as unexplained interindividual or intraindividual variability. Possibly, prediction could improve after adding more covariates such as state of disease progression, age, sex, and others, but this would require a larger patient population. The selected model had the best ability to explain observed data among all the tested models. If a model is having too many parameters, there is always a possibility that it will be biased toward the data used during estimation. The selected ''best'' model has 27 parameters, and its ability to predict new patients' doseresponse should be tested with a new data set.
An important issue in duodenal levodopa infusion treatment is how to individually adjust morning bolus dose and continuous infusion rate as fast and accurate as possible. To address this, we foresee a potential use of this type of PKPD model for in numero simulation experiments, which can assist during dose adjustments. Simulations may also be helpful for training purposes to illustrate the expected outcome of certain dosages for typical, sensitive, or tolerant patients.
